About us
ViaBio Pharma
is a leading regional company specializing in marketing and consulting services for biological, biosimilar, pharmaceutical, and specialized nutritional companies. We are committed to delivering tailored business solutions that drive growth and innovation in the healthcare industry. Our services extend across marketing, logistics, clinical trials, and comprehensive business consulting, ensuring success at every stage of your company’s development.
Our Vission
To be the premier partner for companies in the life sciences and healthcare sectors, helping them overcome market challenges and achieve their strategic objectives through innovative solutions, expert consultancy, and a deep understanding of market dynamics.
Our Mission
Our mission is to empower companies in the healthcare sector by providing strategic marketing, consulting, and business solutions. We specialize in guiding businesses to achieve sustainable growth by managing sales and marketing teams, designing and executing impactful marketing and advertising campaigns, conducting comprehensive market research, and driving innovation.
Leadership Team
Dr. Rula Al Qasem
Managing Partner
With more than 30 years of experience leading organizations like Eli Lilly, AstraZeneca, and Axantia in the Middle East, Dr. Rula Al Qasem brings unparalleled expertise in managing sales and marketing teams, as well as designing and executing impactful marketing campaigns. Her leadership has consistently driven growth for healthcare businesses across the region.
Dr. Omar Astatah
Visionary Leader
Dr. Omar Astatah, with over 20 years of experience in the healthcare, nutritional, and pharmaceutical sectors, is a visionary leader passionate about innovation. His expertise in market research, marketing strategy, and business consulting enables him to identify high-potential opportunities and transform them into successful ventures. Dedicated to investing in cutting-edge health solutions, he is committed to advancing MENA health standards with particular focusing on emerging markets.